Abstract:Background: Virus-like particles (VLPs) can be efficiently produced by heterologous expression of viral structural proteins in yeast. Due to their repetitive structure, VLPs are extensively used for protein engineering and generation of chimeric VLPs with inserted foreign epitopes. Hamster polyomavirus VP1 represents a promising epitope carrier. However, insertion of large sized protein sequences may interfere with its self-assembly competence. The co-expression of polyomavirus capsid protein VP1 with minor capsid protein VP2 or its fusion protein may result in pseudotype VLPs where an intact VP1 protein mediates VLP formation. In the current study, the capacity of VP1 protein to self-assemble to VLPs and interact with the modified VP2 protein has been exploited to generate pseudotype VLPs displaying large-sized antibody molecules. Results: Polyomavirus-derived pseudotype VLPs harbouring a surface-exposed functionally active neutralizing antibody specific to hepatitis B virus (HBV) surface antigen (HBsAg) have been generated. The pseudotype VLPs consisting of an intact hamster polyomavirus (HaPyV) major capsid protein VP1 and minor capsid protein VP2 fused with the anti-HBsAg molecule were efficiently produced in yeast Saccharomyces cerevisiae and purified by density-gradient centrifugation. Formation of VLPs was confirmed by electron microscopy. Two types of pseudotype VLPs were generated harbouring either the single-chain fragment variable (scFv) or Fc-engineered scFv on the VLP surface. The antigen-binding activity of the purified pseudotype VLPs was evaluated by ELISA and virus-neutralization assay on HBV-susceptible primary hepatocytes from Tupaia belangeri. Both types of the pseudotype VLPs were functionally active and showed a potent HBV-neutralizing activity comparable to that of the parental monoclonal antibody. The VP2-fused scFv molecules were incorporated into the VLPs with higher efficiency as compared to the VP2-fused Fc-scFv. However, the pseudotype VLPs with displayed VP2-fused Fc-scFv molecule showed higher antigen-binding activity and HBV-neutralizing capacity that might be explained by a better accessibility of the Fc-engineered scFv of the VLP surface. Conclusions: Polyomavirus-derived pseudotype VLPs harbouring multiple functionally active antibody molecules with virus-neutralizing capability may represent a novel platform for developing therapeutic tools with a potential application for post-exposure or therapeutic treatment of viral infections.

Synthesis and Assembly of Hepatitis B Virus-Like Particles in a Pichia pastoris Cell-Free System

Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications

Assessing Sequence Plasticity of A Virus-Like Nanoparticle by Evolution Toward A Versatile Scaffold for Vaccines and Drug Delivery

Virus-like particles: models for assembly studies and foreign epitope carriers

Bacterial superglue enables easy development of efficient virus-like particle based vaccines

On-column refolding and off-column assembly of parvovirus B19 virus-like particles from bacteria-expressed protein

Exploration on the Expression and Assembly of Virus-Like Particles

Production in Pichia pastoris and characterization of genetic engineered chimeric HBV/HEV virus-like particles

Assembly and Characterization of HBc Derived Virus-like Particles with Magnetic Core

Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell Pool

Virus-like particles: flexible platforms for vaccine development

A VLP vaccine platform comprising the core protein of hepatitis B virus with N-terminal antigen capture

Chimeric hepatitis B surface antigen virus-like particles expressing the strep A epitope p*17 elicit a humoral immune response in mice

Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen

Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery

Process monitoring of virus‐like particle reassembly by diafiltration with UV/Vis spectroscopy and light scattering

Stability and integrity of self-assembled bovine parvovirus virus‐like particles (BPV‐VLPs) of VP2 and combination of VP1VP2 assisted by baculovirus-insect cell expression: a potential logistical platform for vaccine deployment

Upscaling production of immunogenic poliovirus virus-like particles in Pichia Pastoris by controlled fermentation

Virus-like Particle Vaccines and Platforms for Vaccine Development

Virus-like particles as powerful vaccination strategy against human viruses

Combinatorial Approach to Hepadnavirus-Like Particle Vaccine Design